| Pharmaceutical Information |
| Drug Name |
Oxymorphone |
| Drug ID |
BADD_D01648 |
| Description |
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation. |
| Indications and Usage |
For the treatment of moderate-to-severe pain. |
| Marketing Status |
Prescription; Discontinued |
| ATC Code |
N02AA11 |
| DrugBank ID |
DB01192
|
| KEGG ID |
D08323
|
| MeSH ID |
D010111
|
| PubChem ID |
5284604
|
| TTD Drug ID |
D02NSF
|
| NDC Product Code |
0406-3433 |
| Synonyms |
Oxymorphone | Oxymorphone Hydrochloride | Oxymorphone HCl | Numorphan | Opana |
|
| Chemical Information |
| Molecular Formula |
C17H19NO4 |
| CAS Registry Number |
76-41-5 |
| SMILES |
CN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
